EN
A medical device does not remain chemically “bare” once it contacts blood. Within moments, proteins adsorb to the surface and create a new biological interface. That layer influences what happens next: platelet adhesion, platelet activation, coagulation, complement responses, and eventually the risk of thrombus formation.
For this reason, designing a thromboresistant surface is not simply a matter of making a device slippery or hydrophilic. It requires control of blood–material interactions at the surface while preserving the mechanical and manufacturing performance of the device itself.
The first events after blood contact are strongly influenced by surface chemistry. Adsorbed proteins can change orientation or conformation, exposing sites that encourage platelet attachment. Once platelets become activated, they can recruit additional platelets and participate in coagulation processes.
Surface charge, water affinity, roughness, coating thickness, and local blood flow all affect this interaction. A promising chemistry on a flat laboratory coupon may therefore behave differently after it is applied to a flexible catheter, a fine stent structure, or a complex implant.
This is why coatings for biomedical applications should be evaluated as part of the finished device system rather than judged only by a single material property.
Phosphorylcholine (PC) is one approach to modifying the blood-facing interface. PC is zwitterionic: it contains positive and negative charges while remaining electrically neutral overall. This chemistry can strongly associate with water and form a hydrated surface layer that reduces nonspecific protein adsorption.
SILVERMARS® uses MPC-polymer chemistry in its PC coating platform for implantable and interventional medical devices. The platform is designed to modify the surface of a device without requiring the bulk material itself to provide the desired biological interface.
Research on surface-modified vascular devices supports the broader idea that reducing thrombogenic interactions at the material interface can lower platelet deposition or acute thrombus burden, although performance depends on the specific coating chemistry, device, and test model. [1–3]
Hydrophilic surfaces often attract water and may reduce friction or protein adsorption, but “hydrophilic” and “thromboresistant” are not interchangeable terms. Two hydrophilic coatings can have very different polymer structures, binding methods, durability, and biological responses.
For a blood-contacting medical device, engineers should therefore evaluate how the coating contributes to a thromboresistant surface at the blood–material interface. Does it reduce nonspecific protein adsorption? Does it remain attached under bending and flow? Is the chemistry stable after sterilization? Does the finished device show improved hemocompatibility in a relevant test system?
These questions are more useful than relying on a broad surface label.
A coating intended for blood contact must survive the same practical stresses as the device. Flexible components may bend repeatedly. Stents may be crimped, delivered, and expanded. Catheters may move through tortuous anatomy. Sterilization and storage can also change surface properties.
Evaluation should therefore connect three levels: surface chemistry, coating integrity, and device-level biological performance. The goal is not to claim that a surface can eliminate thrombosis in every situation. It is to demonstrate that the selected surface strategy performs consistently for its intended use.
For manufacturers, this is one of the practical advantages of surface-coating technologies: biological functionality can be engineered at the interface without redesigning the entire bulk material of the device.
A thromboresistant surface is designed to reduce material-driven events associated with clot formation, particularly unfavorable protein adsorption and platelet activation.
No. Coating performance is only one part of device thrombosis risk. Geometry, blood flow, procedure, patient factors, and clinical management also matter.
Because coating behavior can change with real device geometry, sterilization, bending, expansion, storage, and simulated use. Testing the finished device provides more relevant evidence than testing the coating chemistry alone.
Lenz-Habijan T, Bhogal P, Peters M, et al. Hydrophilic stent coating inhibits platelet adhesion on stent surfaces: Initial results in vitro. Cardiovascular and Interventional Radiology. 2018;41(11):1779–1785.
White TG, Santhumayor BA, Turpin J, et al. Flow diverter surface modifications for aneurysm treatment: A review of the mechanisms and data behind existing technologies. Interventional Neuroradiology. 2026;32(1):109–125.
Marosfoi M, Clarencon F, Langan ET, et al. Acute thrombus formation on phosphorylcholine surface modified flow diverters. Journal of NeuroInterventional Surgery. 2018;10(4):406–411.
